Oregovomab

Identification

Name
Oregovomab
Accession Number
DB04964
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.

Protein structure
Db04964
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Monoclonal antibody B43.13
  • Oregovamab
  • Oregovomab
External IDs
B 4313 / MAb-B 4313 / MAb-B43.13
International/Other Brands
OvaRex
Categories
UNII
HX101E7L6S
CAS number
213327-37-8

Pharmacology

Indication

Investigated for use/treatment in ovarian cancer.

Pharmacodynamics

Oregovomab is well tolerated and induces multiple antigen-specific immune responses, maintained during concomitant chemotherapy. A significant survival benefit has been observed in patients mounting a T-cell response to CA125 and/or autologous tumor. Vaccination with oregovomab may stimulate a host cytotoxic immune response against tumor cells that express CA125.

Mechanism of action

Oregovomab targets the circulating tumour-associated antigen CA 125, which is shed from the surface of human ovarian cancer cells; the antibodies induce broad cellular and humoral immune responses against CA 125 via complex formation. Unlike free CA 125, CA 125-oregovomab complexes can prime dendritic cells, leading to downstream activation of T cells.

TargetActionsOrganism
UMucin-16Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Oregovomab.
AbituzumabThe risk or severity of adverse effects can be increased when Oregovomab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Oregovomab.
AdecatumumabThe risk or severity of adverse effects can be increased when Oregovomab is combined with Adecatumumab.
AducanumabThe risk or severity of adverse effects can be increased when Oregovomab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Oregovomab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oregovomab.
AlirocumabThe risk or severity of adverse effects can be increased when Oregovomab is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when Oregovomab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when Oregovomab is combined with AMG 108.
Food Interactions
Not Available

References

General References
  1. Berek JS: Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther. 2004 Jul;4(7):1159-65. [PubMed:15268682]
  2. Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, Nicodemus CF: CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol. 2004 Aug;94(2):340-51. [PubMed:15297171]
  3. Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, Swenerton KD: A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1023-34. [PubMed:16343178]
  4. Authors unspecified: Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs R D. 2006;7(6):379-83. [PubMed:17073521]
External Links
PubChem Substance
347909863
Wikipedia
Oregovomab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentAdvanced Ovarian Cancer / Cancer of the Ovary / Neoplasms, Ovarian / Ovarian Cancer Stage III / Recurrent Ovarian Cancer1
1, 2RecruitingTreatmentOvarian Epithelial Cancer1
1, 2TerminatedTreatmentNeoplasms, Ovarian1
2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Resectable Pancreatic Carcinoma / Stage I Pancreatic Cancer / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage II Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2CompletedTreatmentNeoplasms, Ovarian1
2TerminatedTreatmentCancer of the Ovary1
2TerminatedTreatmentNeoplasms, Ovarian1
2Unknown StatusTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer2
3TerminatedTreatmentCancer of the Ovary1
Not AvailableWithdrawnTreatmentFallopian Tube Carcinoma / Primary Peritoneal Carcinoma / Recurrent Ovarian Carcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.
Gene Name
MUC16
Uniprot ID
Q8WXI7
Uniprot Name
Mucin-16
Molecular Weight
1519158.08 Da
References
  1. Berek JS: Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther. 2004 Jul;4(7):1159-65. [PubMed:15268682]
  2. Authors unspecified: Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs R D. 2006;7(6):379-83. [PubMed:17073521]

Drug created on October 21, 2007 16:23 / Updated on December 14, 2018 05:38